

21st RSC / SCI Medicinal Chemistry Symposium

The organisers invite you to the 21st RSC / SCI Medicinal Chemistry Symposium, Europe's premier biennial Medicinal Chemistry event, focussing on first disclosures and new strategies in Medicinal Chemistry.

Call for Posters

A number of conference places will be reserved for poster presenters and contributions are invited from the whole field of Medicinal Chemistry. Those presenting a poster may also elect to advertise their poster via an oral presentation of a single-slide 'flash' poster. The final submission date is 23rd July 2021, and outcomes will be notified by 11th August.

Registration

Registration is open and fees for the virtual event are:

£230 RSC or SCI member	£115 RSC or SCI student* member, unemployed member, retired member
£270 Non-member	£135 Student non-member

Delegate registration fees include attendance at the virtual technical programme and networking. Only one log-in link will be allocated to each registered delegate.

At the time of registration, you will be asked whether you wish to be considered for face-to-face participation should the opportunity arise. Please see our website for details of additional charges, selection process, and timing.

Organising Committee

Nadia Ahmad, Charles River

Mark Healy, Novartis (Technical Adviser)

Simon Peace, GlaxoSmithKline (Chair)

Jo Pinder, Vertex

Gordon Saxty, Fidelia (Treasurer)

Jamie Scott, AstraZeneca

Chris Swain, Cambridge MedChem Consulting

Nigel Swain, Sosei Heptares

Andrew Williams, Hon Chairman, RSC BMCS


Secretariat Contact

The RSC BMCS secretariat, Maggi Churchouse, +44 (0)1359 221004, maggi@maggichurchouseevents.co.uk.

Websites: www.maggichurchouseevents.co.uk/bmcs/cmc21

Also: www.rscbmcs.org/events and www.soci.org/events

Final announcement and call for posters



21st RSC / SCI Medicinal Chemistry Symposium

Monday-Wednesday, 13th-15th September 2021

Online event, hosted from and held at
Churchill College, Cambridge, UK
with option to register interest in attendance in person



RSC INTEREST GROUP
BIOLOGICAL AND MEDICINAL
CHEMISTRY SECTOR



#CamMedChem21



where science meets business

21st RSC / SCI Medicinal Chemistry Symposium

Overview

Reflecting current trends in medicinal chemistry and pharmaceutical research, the scientific programme will feature lectures on the full range of drug targets, key enabling processes and technologies together with late breaker talks.

This conference will be of interest to both academic and industrial scientists engaged in all aspects of the drug discovery and development process. It will aim to showcase first disclosures of significant new therapeutic agents across all disease areas, and provide a forum for discussion of current topics and thinking at the forefront of medicinal chemistry.

Programme

Monday, 13th September

- 12.30 Lunch for face-to-face attendees, exhibitor videos
13.30 Introduction and welcome
- Session 1
13.35 *Discovery and first structural disclosure of AZD0095, a potent and selective inhibitor of MCT4 for oncology*
Frederick Goldberg, AstraZeneca, UK
14.10 *Structure-guided discovery of a potent and selective USP7 inhibitor*
András Kotschy, Servier Research Institute of Medicinal Chemistry, HU
14.45 *Lenacapavir: a first-in-class phase 2/3 HIV capsid inhibitor with potential for twice yearly dosing*
Jennifer Zhang, Gilead Sciences, US
15.20 Flash poster presentations - session 1 (ten two-minute presentations)
15.40 Posters, networking, and refreshments
- Session 2
16.40 *Translating frontier oncology targets to outsmart cancer™*
Elena Koltun, Revolution Medicines, US
17.15 *Discovery of CFTR modulators for the treatment of cystic fibrosis*
Jeremy Clemens, Vertex, US
17.50 *Mass spectrometry and its role in drug discovery*
Keynote: Dame Carol Robinson, University of Oxford, UK
18.25 Close

Programme (continued)

Tuesday, 14th September

- Session 3
10.30 *Lysine-targeting covalent inhibitors – overcoming difficult-to-drug proteins and resistance*
Matthew Cheeseman, The Institute of Cancer Research, UK
11.05 *Snapshots of cannabinoid receptor 2 agonists on their way to bedside*
Uwe Grether, F Hoffmann-La Roche, CH
11.40 *The identification of GPR52 agonist HTL0041178, a potential therapy for schizoaffective and related psychiatric disorders*
Steve Watson, Sosei Heptares, UK
12.15 Lunch break, exhibitor videos
- Session 4
13.15 *Presentation of the 2021 Malcolm Campbell Memorial Prize by*
Sir Patrick Vallance, Chief Scientific Adviser to the Government of the UK
13.25 *Discovery of selective, CNS-penetrant, reversible Bruton's Tyrosine Kinase (BTK) inhibitors for the treatment of disease progression in multiple sclerosis*
tbci, Biogen, US
14.00 *Discovery of highly soluble inhaled FRAP1 inhibitors with high lung:systemic unbound ratio via application of a novel 3Rs inhaled approach*
Heather Hobbs, GlaxoSmithKline, UK
14.35 *Discovery of IRAK4 inhibitors BAY 845 and BAY 839: first disclosure presentation*
Ulrich Bothe, Bayer, DE
15.10 Flash poster presentations - session 2 (ten two-minute presentations)
15.30 Posters, networking, and refreshments
- Session 5
16.30 *Discovery of potent, selective and brain-penetrant eIF2B activators for the treatment of neurodegenerative diseases*
Maksim Osipov, Denali Therapeutics, US
17.05 *Development of next generation utrophin modulators for Duchenne muscular dystrophy: learning from clinical setbacks*
Angela Russell, University of Oxford, UK
17.40 *Medicines for millions of patients*
The BMCS Hall of Fame 2020 Inductee: **David Rees**, Astex Pharmaceuticals, UK
18.15 Close

Websites: www.maggichurchousevents.co.uk/bmcs/cmc21

Also: www.rscbmcs.org/events and www.soci.org/events



RSC INTEREST GROUP
**BIOLOGICAL AND MEDICINAL
CHEMISTRY SECTOR**



21st RSC / SCI Medicinal Chemistry Symposium

Programme (continued)

Wednesday, 15th September

Session 6

10.30 *Design of advanced γ -secretase modulators by co-ordinated structural replacements and a novel bioisostere*

Rosa Maria Rodríguez Sarmiento, F Hoffmann-La Roche, CH

10.50 *Small molecule degraders of the estrogen receptor*

Thomas Moss, AstraZeneca, UK

11.25 *Advances in small molecules inducing targeted protein degradation*

Ian Collins, The Institute of Cancer Research, UK

11.45 *Proteomics based target deconvolution leads to the discovery of PAPD5 as the target of the HBV-antigen inhibitor Rg7834*

Douglas Thomson, GlaxoSmithKline, DE

12.20 Lunch break, exhibitor videos

Session 7 - Late-breaking Science

13.20 *The COVID Moonshot: SARS-CoV-2 oral antiviral therapeutics from an Open Science Global Collaboration*

Ed Griffen, MedChemica, UK

13.40 *Oral inhibitors of the SARS-CoV-2 main protease for the treatment of COVID-19*

Dafydd Owen, Pfizer Worldwide Research Development and Medicine, US

14.00 *Fragment based discovery of MRTX9768, a selective inhibitor of the PRMT5-MTA complex for the treatment of MTAP/CDKN2A-deleted tumours*

Chris Smith, Mirati Therapeutics, US

14.35 *Discovery of an oral, Ro5 compliant IL17A protein-protein interaction modulator for the treatment of psoriasis*

Mark Andrews, LEO Pharma, DK

15.10 Posters, networking, and refreshments

Session 8

15.40 *Inhibitors and degraders of the BCL6-co-repressor interaction*

Rosemary Huckvale, The Institute of Cancer Research, UK

16.00 *The effect of core replacement on the selective Mcl-1 inhibitor S64315*

Marton Csekei, Servier Research Institute of Medicinal Chemistry, HU

16.20 *Inspiring medicinal chemistry with novel multi-objective optimised ideas: the Novartis Generative Chemistry initiative*

Finton Sirockin, Novartis, CH

16.55 Closing remarks

17.00 Close

Sponsorship and Exhibition Opportunities

We are grateful to our confirmed sponsors who are acknowledged on our website and overleaf. Additional organisations are encouraged to support this renowned event.

The Exhibitor Package is charged at £1,000 and excludes any delegate registrations. Further information about the Package may be found on the website below.

We are grateful to our confirmed sponsors



GlaxoSmithKline



Complexity Simplified



Domainex
Enrich your medicines pipeline



evotec



Selvita



MSD
INVENTING FOR LIFE



astex[®]
pharmaceuticals

